EGFR T790M — resistance to 1st/2nd gen TKIs
Gene: EGFR · Type: mutation
Indications: Non-small cell lung cancer
Linked CIViC Profile: EGFR T790M
Evidence Level Distribution
Level A: 3Level B: 11Level C: 4Level D: 11Level E: 1
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| A | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Erlotinib | 5 |
| D | Predictive | Supports | Resistance | Lung Cancer | Multikinase Inhibitor AEE788,Gefitinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Osimertinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Osimertinib | 5 |
| B | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Dacomitinib | 4 |
| B | Prognostic | Supports | Poor Outcome | Lung Non-small Cell Carcinoma | 4 | |
| B | Prognostic | Supports | Poor Outcome | Lung Non-small Cell Carcinoma | 4 | |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Rociletinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Osimertinib | 4 |
| B | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Afatinib | 4 |
| C | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Gefitinib,Erlotinib | 4 |
| D | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Lapatinib | 4 |
| B | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Gefitinib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib,Pemetrexed | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Rociletinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Osimertinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Osimertinib | 3 |
| B | Predictive | Supports | Resistance | Lung Adenocarcinoma | Gefitinib,Erlotinib | 3 |
| B | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Erlotinib,Gefitinib | 3 |
| B | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Gefitinib | 3 |